Related Experiment Videos

[Cefminox concentration in tissues and clinical efficacy of cefminox in acute peritonitis]

Insights

Cefminox sodium (CMNX) demonstrated high efficacy and safety in treating acute peritonitis, showing excellent or good clinical responses in all patients. This beta-lactamase-resistant antibiotic achieved significant drug concentrations in infected tissues, supporting its use in peritonitis chemotherapy.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Surgical Infections

Background:

  • Cefminox sodium (CMNX), a novel semisynthetic cephamycin, exhibits broad-spectrum antibacterial activity and resistance to beta-lactamase.
  • Its in vivo efficacy surpasses in vitro activity, making it a candidate for treating severe bacterial infections.

Observation:

  • CMNX was administered intravenously to 24 patients with acute peritonitis at daily doses ranging from 0.5 g to 2 g.
  • Clinical responses were excellent in 9 cases, good in 14, and fair in 1, with no observed adverse effects.
  • Bacterial eradication was noted for most isolated organisms, including Escherichia coli and Pseudomonas aeruginosa.

Findings:

  • CMNX achieved significant concentrations in infected tissues and body fluids, with higher levels in purulent ascites (47.2 ± 38.5 µg/ml) and infected appendix wall (32.2 ± 21.7 µg/g).
  • Concentrations in infected tissues exceeded those in non-infected tissues, and in empyemic appendicitis, pus levels were higher than in the appendix wall.
  • The drug effectively treated various forms of acute peritonitis, including appendicitis and panperitonitis.

Implications:

  • Cefminox sodium is a highly effective and safe therapeutic option for acute peritonitis.
  • Its pharmacokinetic profile supports its use in managing intra-abdominal infections, particularly those involving beta-lactamase-producing bacteria.
  • Further research may explore optimal dosing and its role in combination therapies for complex surgical infections.

Related Concept Videos